Explore 3 Stock Ideas & Industry Insights Download Free Report

Earnings

American Battery Technology Company (NASDAQ:ABAT) Stock: Fiscal Q1 2027 Earnings, Revenue and Black Mass Export Update

The company said revenue in the period was affected by the federal export restriction on black mass, which limited its ability to sell certain materials. It said it received approval to export US$100 million of black mass product and expects revenue to begin recovering …

Nitish Kishor | 14 November 2026

Jade Biosciences (NASDAQ:JBIO) Stock: Q3 2026 Earnings, JADE101 Trial Progress and Equity Financing Update

Interest income was US$4,629 thousand versus US$2,254 thousand. Net loss was US$(35,055) thousand, versus US$(25,175) thousand, or US$(0.42) per common share versus US$(0.48). Weighted average shares were 71,763,164 versus 39,584,489.

Nitish Kishor | 14 November 2026

PowerCompute (NASDAQ:PWCM) Stock: Q3 2026 Earnings, Bitcoin Production and Debt Repayment Update

Mining margin was 50.7%, versus 29.0% in the second quarter of 2026 and 49.0% in the third quarter of 2025. Energy cost to mine one Bitcoin, net of curtailment and energy sales, was approximately US$35,000 versus approximately US$58,000, and blended net power cost was …

Nitish Kishor | 14 November 2026

Immunic (NASDAQ:IMUX) Stock: Q3 2026 Earnings, NDA Readiness Spending and Stock Compensation Charge

These increases were partly offset by a US$1.8 million decrease for its ENSUREClinical Trialsand a US$1.0 million decrease for its CALLIPER clinical trial.

Nitish Kishor | 14 November 2026

SBC Medical Group Holdings (NASDAQ:SBC) Stock: Q3 2026 Earnings, Revenue Growth and Cash Position

Cost of revenues was US$16,402,500 versus US$12,741,748, equal to 28.00% ofRevenueversus 29.39%.Gross Profitwas US$42,179,020 versus US$30,611,487, or 72.00% of revenue versus 70.61%.

Nitish Kishor | 14 November 2026

PDS Biotechnology (NASDAQ:PDSB) Stock: Q3 2026 Earnings, PIPE Financing and PDS0301 Program Update

The company said it continued to prioritize PDS0301, its investigational tumor-targeted IL-12 immunocytokine, as its lead development program, with ongoingClinical Trialsat the National Cancer Institute.

Nitish Kishor | 14 November 2026

Silexion Therapeutics (NASDAQ:SLXN) Stock: Q3 2026 Earnings, SIL204 Phase 2/3 Trial Start and Going Concern Disclosure

The company said third-quarter 2026 research expenses primarily related to initiation of its Phase 2/3 clinical trial for SIL204, in which the first patient was dosed on September 30, 2026. General and administrative expenses were US$1,398 thousand, versus US$1,135 thousand, an increase of 27.3%, …

Nitish Kishor | 14 November 2026

Suncrete (NASDAQ:RMIX) Stock: Q3 2026 Earnings, Ready-Mix Revenue and Revised 2026 Outlook

Net income was US$78 thousand, versus a net loss of US$37.1 million in the second quarter of 2026 andNet Incomeof US$4.6 million a year earlier. Adjusted EBITDA, a non-GAAP measure, was US$22.4 million, versus US$13.5 million in the second quarter and US$13.7 million a …

Nitish Kishor | 14 November 2026

Lifeward (NASDAQ:LFWD) Stock: Q3 2026 Earnings, Gross Margin and Going Concern Disclosure

Gross profit was US$1,487 thousand, or 27.4% of revenue, versus US$2,707 thousand, or 43.7%. The company attributed the lower margin primarily to adverse foreignExchange Ratefluctuations, revenue sharing expense, higher freight costs and tariffs. For the nine months, revenue was US$15,974 thousand versus US$16,953 thousand, …

Nitish Kishor | 14 November 2026

REalloys (NASDAQ:ALOY) Stock: Q3 2026 Earnings, Rare Earth Metallization Projects and Army Lease Term Sheet

The company noted that period comparisons are affected by changes in its reporting entity: the reverseRecapitalizationclosed on February 24, 2026, and Blackbox.io was deconsolidated on May 5, 2026. For the nine months, net revenues were US$1,923 thousand versus US$626 thousand, and gross margin was …

Nitish Kishor | 14 November 2026
Support

Hi! How can we help you today?

Loading…